Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)

Annals of the Rheumatic Diseases

Volumn 69, Issue SUPPL. 1, 2010, Pages

  Wagner, E F ^a  

^a BBVA University Institute for Economic and Social Analysis University of Alcalá   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G 6 31; PROTEIN FOS; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR JUNB; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY;

BONE DEVELOPMENT; CELL FUNCTION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; ANTIANGIOGENIC THERAPY; CELL ACTIVITY; CELL DIFFERENTIATION; CYTOKINE RESPONSE; HUMAN; INFLAMMATORY DISEASE; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SKIN INFLAMMATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE DEVELOPMENT; DERMATITIS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; PSORIASIS; TRANSCRIPTION FACTOR AP-1;

EID: 75749109330     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.119396     Document Type: Review

References (16)

1. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
2. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
3. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005;208:126-40.
4. Jochum W, David JP, Elliott C, et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 2000;6:980-4.
5. Sabatakos G, Sims NA, Chen J, et al. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 2000;6:985-90.
6. Eferl R, Hoebertz A, Schilling AF, et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 2004;23:2789-99.
7. Eferl R, Hasselblatt P, Rath M, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A 2008;105:10525-30. Epub 18 July 2008.
8. Karreth F, Hoebertz A, Scheuch H, et al. The AP1 transcription factor Fra2 is required for efficient cartilage development. Development (Cambridge, England) 2004;131:5717-25.
9. Bozec A, Bakiri L, Hoebertz A, et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signaling and hypoxia. Nature 2008;454:221-5. Epub 11 June 2008.
10. Zenz R, Wagner EF. Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol 2006;38:1043-9.
11. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001;20:2413-23.
12. Mehic D, Bakiri L, Ghannadan M, et al. Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol 200;124:212-20.
13. Zenz R, Scheuch H, Martin P, et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003;4:879-89.
14. Meixner A, Zenz R, Schönthaler HB, et al. Epidermal JunB represses G-CSF transcription and affects hematopoiesis and bone formation. Nat Cell Biol 2008;10:1003-11. Epub 20 July 2008.
15. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75.
16. Zenz R, Eferl R, Scheinecker C, et al. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther 2008;10:201.